In addition, prospective observation of BRCA1 and BRCA2 pathogenic variant carriers in the United Kingdom and Ireland (median observation period of 5.9 years and 5.3 years, respectively) showed that those with BRCA2 pathogenic variants showed a two to five times higher incidence of prostate cancer than that of the general population [20]. This evidence concerns the gene BRCA2 and prostate carcinoma.